Back to mobile site

Goldman Sachs Resumes Neurocrine Bio. (NBIX) at Buy

June 2, 2026 5:07 AM EDT Send to a Friend
Goldman Sachs analyst Corinne Johnson resumes coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login